ArticlePloS one2020
Optimised generation of iPSC-derived macrophages and dendritic cells that are functionally and transcriptionally similar to their primary counterparts.
Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 55 citations in OpenAlex.
- Induced pluripotent stem cell-derived macrophages enable broad modeling of human inflammasome signaling.Cell reports methods · 2026Article
- Induced pluripotent stem cell-derived macrophages (iMacs) in translational medicine: Disease models, drug testing, and therapeutic applications.Molecular biology reports · 2026Review
- Harnessing intermediate-scale bioreactors for next-generation macrophage production and application.Nature protocols · 2026Review
- Naringin promotes cancer immunity by inducing cross-presentation by antigen-presenting cells.Cancer immunology, immunotherapy : CII · 2026Article
- Potential of CAR-Macrophages Derived from Induced Pluripotent Stem Cells (iMacs) for Solid Tumor Therapy.Cell biochemistry and biophysics · 2026Review
- Defined culture conditions improve functional properties of mature iPSC-derived macrophages for therapeutic screening.Stem cell research & therapy · 2026Article
- Optimizing the Method for Differentiation of Functional Platelets from Human Induced Pluripotent Stem Cells.Stem cell reviews and reports · 2026Article
- Protocol to generate immunocompetent human heart-macrophage assembloids for the study of immune-cardiac interactions.STAR protocols · 2026Article
- Generation and characterization of iPSC models from HIV-1-positive individuals with divergent clinical outcomes.Stem cell reports · 2026Article
- Human pluripotent stem cell-derived innate and adaptive immune cells for cancer immunotherapy.Cell stem cell · 2026Review
- Modeling myeloid cell development in health and disease using induced pluripotent stem cells.Frontiers in immunology · 2026Review
- Chimeric antigen receptor macrophages therapy for glioblastoma: challenges and opportunities from preclinical evidence to clinical translation.Frontiers in immunology · 2026Review
- CAR-macrophages in solid tumors: promise, progress, and prospects.NPJ precision oncology · 2025Review
- In Vitro Skin Models as Non-Animal Methods for Dermal Drug Development and Safety Assessment.Pharmaceutics · 2025Review
- Induced Pluripotent Stem Cell-Based Cancer Immunotherapy: Strategies and Perspectives.Biomedicines · 2025Review
- The Application of iPSCs in Tumour Immunotherapy.Expert reviews in molecular medicine · 2025Review
- Comprehensive review of macrophage models: primary cells and immortalized lines across species.Frontiers in immunology · 2025Review
- Ultrasound-triggered three dimensional hyaluronic acid hydrogel promotes in vitro and in vivo reprogramming into induced pluripotent stem cells.Bioactive materials · 2024Article
- Building a human lung from pluripotent stem cells to model respiratory viral infections.Respiratory research · 2024Review
- Stemformatics data portal enables transcriptional benchmarking of lab-derived myeloid cells.Stem cell reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Induced pluripotent stem cells (iPSC) offer the possibility to generate diverse disease-relevant cell types, from any genetic background with the use of cellular reprogramming and directed differentiation. This provides a powerful platform for disease modeling, drug screening and cell therapeutics. The critical question is how the differentiated iPSC-derived cells translate to their primary counterparts. Our refinement of a published differentiation protocol produces a CD14+ monocytic lineage at a higher yield, in a smaller format and at a lower cost. These iPSC-derived monocytes can be further differentiated into macrophages or dendritic cells (DC), both with similar morphological and functional profiles as compared to their primary counterparts. Transcriptomic analysis of iPSC-derived cells at different stages of differentiation as well as comparison to their blood-derived counterparts demonstrates a complete switch of iPSCs to cells expressing a monocyte, macrophage or DC specific gene profile. iPSC-derived macrophages respond to LPS treatment by inducing expression of classic macrophage pro-inflammatory response markers. Interestingly, though iPSC-derived DC show similarities to monocyte derived DC, they are more similar transcriptionally to a newly described subpopulation of AXL+ DC. Thus, our study provides a detailed and accurate profile of iPSC-derived monocytic lineage cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.